EFA Annual Impact Report 2025 is now available!
EFA has published its Annual Impact Report 2025, looking back at a year of stronger patient advocacy, deeper community engagement and growing action on...
EFA at the SynAir-G workshop: connecting data, patients and policy on indoor air quality in schools
On 8 June 2026 in Brussels, EFA joined the SynAir-G third workshop "Smart Synergies for Action: Connecting Data, Patients and Policy on Indoor Air Quality."...
EFA and SynAir-G project discuss the importance of indoor air quality and children’s health at the European Parliament
On 11 June 2026, EFA joined forces with the EU-funded SynAir-G project at the European Parliament for a roundtable on indoor air quality and children's...
EU’s proposal to restrict PFAS might be a threat for patients relying on inhaled medicines
Per- and polyfluoroalkyl substances, or PFAS, a broad group of chemicals often referred to as “forever chemicals”, raise serious environmental and...
EFA Community marks World Asthma Day 2026 with #EmpoweredToBreathe and practical information for daily life with asthma
Today, on 5 May, the EFA Community marks World Asthma Day 2026 under the theme #EmpoweredToBreathe – taking control of asthma every day.
Across...
EFA’s take on EMA’s updates on clinical trials during public health emergencies in Europe
Imagine you are a patient participating in a clinical trial and half-way through it is modified or postponed due...
Celebrating 35 Years of EFA: new leadership and a growing patient community at the AGM and Community Meeting in Malta
The EFA Community gathered in Malta for its Annual General Meeting and Community Meeting, hosted by the Malta Eczema Society. 31 member organisations from...
Three EFA community asks on EMA’s patient experience data
Medicines are assessed on quality, safety and efficacy. Patients and carers experience the full picture: what improves day to day, what trade-offs come...
EFA community priorities for an EU framework on climate resilience and risk management
Europe is already feeling the climate crisis. The continent is warming twice as fast as the global average, which means more frequent and intense heatwaves,...
EU critical medicines list updated for 2026: EFA’s take on progress and gaps for patients
The European Medicine’s Agency (EMA) has published the updated Union list of critical medicines for 2026. This list identifies medicines whose continued...
Making skin diseases visible: a call for holistic EU action
On 26 February, EFA President Marcia Podestà spoke at the European Parliament event ‘More than just skin: turning global commitments on skin...
EFA contributes to EAACI Guidelines on the importance of urban green spaces for the prevention of allergy and asthma
The European Academy of Allergy and Clinical Immunology (EAACI) published guidelines on the importance of green space in urban environments for allergy...
Cyprus Council Presidency: EFA’s priorities on EU health funding, Safe Hearts plan and affordable housing
From January to June 2026, Cyprus holds the presidency of the Council of the European Union under the motto ‘An Autonomous Union. Open to the World’.
For...
European Commission launches new health package – What does it mean for our community
The European Commission proposed a new set of plans labelled “Health Package” that might bring faster access to new therapies and medical devices for...
Breaking the invisible burden: atopic eczema patients bring their lived reality to the European Parliament
Last week, the EFA Atopic Eczema patient community brought the lived experience of atopic eczema patients to the European Parliament through an immersive...
EU Clean Air Forum 2025: governments must cut emissions and implement air quality rules to protect lung health
The 5th EU Clean Air Forum in Bonn brought together policymakers, scientists and civil society to discuss air quality in Europe. EFA represented people...
EFA brings patients’ perspective to EMA webinar on shortages
On Tuesday 4 November, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) participated in an European Medicines Agency...
A patient lens on the EU Biotech act
On 7 November 2025, the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) sent its feedback to the European Commission’s...
European Respiratory Patient Academy: training patient advocates for a stronger respiratory future in Europe
The first training session of the European Respiratory Patient Academy brought together 42 patient advocates from 23 countries for four days in Prague...
EFA addresses WHO RC75 and urges action on lung and skin health resolutions
Copenhagen hosted the 75th session of the WHO Regional Committee for Europe (RC75), where governments, WHO officials and civil-society organisations reviewed...